Scarica l'app Stockscreener
30.27
5.18%
1.49
Dopo l'orario di chiusura:
31.50
1.23
+4.06%
Precedente Chiudi:
$28.78
Aprire:
$28.82
Volume 24 ore:
312.88K
Relative Volume:
0.62
Capitalizzazione di mercato:
$1.44B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+2.61%
1M Prestazione:
+20.26%
6M Prestazione:
+171.72%
1 anno Prestazione:
+59.23%
Intervallo 1D:
$28.03
$30.50
Intervallo di 1 settimana:
$27.81
$31.00
Portata 52W:
$7.13
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Nome
Rapport Therapeutics Inc
Settore
Industria
Telefono
857-321-8020
Indirizzo
99 HIGH STREET, BOSTON
Confronta RAPP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
30.27 | 1.37B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-19 | Iniziato | BTIG Research | Buy |
| 2025-09-16 | Iniziato | Truist | Buy |
| 2025-08-06 | Iniziato | H.C. Wainwright | Buy |
| 2025-04-08 | Iniziato | Citizens JMP | Mkt Outperform |
| 2024-07-02 | Iniziato | Jefferies | Buy |
| 2024-07-02 | Iniziato | Stifel | Buy |
| 2024-07-02 | Iniziato | TD Cowen | Buy |
Mostra tutto
Rapport Therapeutics Inc Borsa (RAPP) Ultime notizie
Wall Street Zen Upgrades Rapport Therapeutics (NASDAQ:RAPP) to Hold - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Trading Up 5.4%Here's Why - MarketBeat
Rapport Therapeutics Shapes Focused Clinical Neuroscience Programs - Kalkine Media
HC Wainwright Issues Optimistic Forecast for RAPP Earnings - Defense World
FY2027 Earnings Forecast for RAPP Issued By HC Wainwright - MarketBeat
HC Wainwright & Co. Maintains Rapport Therapeutics (RAPP) Buy Recommendation - Nasdaq
H.C. Wainwright raises Rapport Therapeutics stock price target to $40 on strong seizure drug data - Investing.com Canada
Rapport Therapeutics (NASDAQ:RAPP) Receives “Buy” Rating from BTIG Research - Defense World
Rapport Therapeutics, Inc. (RAPP) Is Up 9.03% in One Week: What You Should Know - sharewise.com
Rapport Therapeutics (NASDAQ:RAPP) Earns Buy Rating from BTIG Research - MarketBeat
BTIG Reiterates Rapport Therapeutics (RAPP) Buy Recommendation - Nasdaq
Citizens reiterates Market Outperform rating on Rapport Therapeutics stock By Investing.com - Investing.com Canada
Rapport Therapeutics (RAPP) Valuation Check After a 60% Year-to-Date Share Price Surge - Yahoo Finance
RAP-219 Phase 2a Seizure Data and Planned Pivotal Trials Might Change The Case For Investing In Rapport Therapeutics (RAPP) - Yahoo Finance
Affinity Asset Advisors LLC Purchases Shares of 199,643 Rapport Therapeutics, Inc. $RAPP - Defense World
Wall Street Zen Downgrades Rapport Therapeutics (NASDAQ:RAPP) to Sell - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Downgraded to Sell Rating by Wall Street Zen - Defense World
Rapport Therapeutics Announces Positive Phase 2a Post-Hoc Analysis of RAP-219 Demonstrating Early Efficacy in Drug-Resistant Focal Onset Seizures - Quiver Quantitative
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures - The Manila Times
Rapport Therapeutics Announces New Data and Post Hoc - GlobeNewswire
Rapport Therapeutics (RAPP) Valuation After Key Phase 2a Epilepsy Data Presentation Announcement - Sahm
Will Rapport Therapeutics Inc. stock see PE expansionJuly 2025 Momentum & Low Drawdown Momentum Trade Ideas - Newser
Is Rapport Therapeutics Inc. stock trading at a premium valuationWeekly Market Report & Weekly High Conviction Trade Ideas - Newser
(RAPP) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Rapport Therapeutics (RAPP) Stock Analysis Report | Financials & Insights - Benzinga
Rapport Therapeutics COO Cheryl Gault Sells 5,000 Shares - TradingView
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Wall Street Analysts See a 74.99% Upside in Rapport Therapeutics, Inc. (RAPP): Can the Stock Really Move This High? - sharewise.com
Rapport Therapeutics (RAPP) Is Down 11.3% After Positive Phase 2a Data and $269M Offering – Has the Bull Case Changed? - Sahm
Rapport Therapeutics (NASDAQ:RAPP) Shares Up 6.1%Here's What Happened - MarketBeat
A Look at Rapport Therapeutics’s Valuation as New RAP-219 Phase 2a Data Presentation Approaches - Sahm
How does Rapport Therapeutics Inc (RAPP) change from a tortoise to a hare? - Setenews
Could RAP-219’s Upcoming Data Reveal a Turning Point for Rapport Therapeutics’ Pipeline Strategy (RAPP)? - simplywall.st
Rapport Therapeutics to Present New Phase 2a Data Analysis - GlobeNewswire
Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting - Yahoo Finance
What Analyst Ratings Reveal About Sagar Systech Limiteds Future ValueStock Buy Signals & Fast Growing Trading Plans - earlytimes.in
(RAPP) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Can Rapport Therapeutics Inc. stock outperform in 2025 bull marketStop Loss & Long-Term Growth Stock Strategies - newser.com
Rapport Therapeutics (NASDAQ:RAPP) Coverage Initiated at BTIG Research - MarketBeat
Can trapped investors hope for a rebound in Rapport Therapeutics Inc. - newser.com
What institutional flow reveals about Rapport Therapeutics Inc.Weekly Stock Analysis & Daily Entry Point Trade Alerts - newser.com
Will Rapport Therapeutics Inc. stock pay special dividendsJuly 2025 Reactions & Breakout Confirmation Trade Signals - newser.com
This Extreme Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Analyzing Rapport Therapeutics Inc. with risk reward ratio chartsTreasury Yields & Safe Capital Growth Tips - newser.com
BTIG Research Initiates Coverage on Rapport Therapeutics With Buy Rating, $47 Price Target - MarketScreener
BTIG Initiates Coverage of Rapport Therapeutics (RAPP) with Buy Recommendation - Nasdaq
What candlestick patterns are forming on Rapport Therapeutics Inc.Gap Up & Verified Entry Point Signals - newser.com
Why Rapport Therapeutics Inc. stock is a value investor pick2025 Technical Overview & Technical Pattern Based Signals - newser.com
Published on: 2025-11-18 22:13:16 - newser.com
Rapport Therapeutics Inc Azioni (RAPP) Dati Finanziari
Non sono disponibili dati finanziari per Rapport Therapeutics Inc (RAPP). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Rapport Therapeutics Inc Azioni (RAPP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Gault Cheryl | Chief Operating Officer |
Nov 26 '25 |
Sale |
30.10 |
5,000 |
150,486 |
171,928 |
| Ceesay Abraham | Chief Executive Officer |
Nov 17 '25 |
Sale |
25.19 |
5,833 |
146,931 |
573,746 |
| Ceesay Abraham | Chief Executive Officer |
Nov 17 '25 |
Sale |
25.20 |
5,083 |
128,116 |
35,978 |
| Bredt David | Chief Scientific Officer |
Nov 17 '25 |
Sale |
25.19 |
8,500 |
214,091 |
401,142 |
| Bredt David | Chief Scientific Officer |
Oct 15 '25 |
Sale |
25.79 |
8,500 |
219,196 |
409,642 |
| Ceesay Abraham | Chief Executive Officer |
Oct 15 '25 |
Sale |
25.81 |
5,833 |
150,541 |
579,579 |
| Ceesay Abraham | Chief Executive Officer |
Oct 15 '25 |
Sale |
25.81 |
5,083 |
131,189 |
41,061 |
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):